RNA sequencing revealed the impact of avenciguat on bleomycin-induced skin fibrosis in mice (Supplementary Fig. S1, available at Rheumatology online), showing down-regulated genes linked to IFN signalling, typically elevated in SSc patients, correlating with disease severity and treatment effectiveness [4]. The gene discussed is IFNA1; the disease is systemic sclerosis.